KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Cost of Revenue (2016 - 2025)

Travere Therapeutics' Cost of Revenue history spans 12 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Cost of Revenue changed 0.0% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $10.3 million, up 33.5%, while the annual FY2025 figure was $10.3 million, 33.51% up from the prior year.
  • Cost of Revenue reached $2.6 million in Q4 2025 per TVTX's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $4.7 million in Q1 2025 to a low of -$1.1 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $2.0 million, with a median of $1.6 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: crashed 151.64% in 2021, then soared 425.81% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at -$1.1 million in 2021, then soared by 181.12% to $868000.0 in 2022, then skyrocketed by 425.81% to $4.6 million in 2023, then crashed by 44.06% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Cost of Revenue are $2.6 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025).